What genomic profiling can reveal
Tumor profiling may report single-nucleotide variants, insertions or deletions, copy-number changes, structural rearrangements, and other molecular features. The scope depends on assay design and specimen quality. A negative result on a limited panel cannot exclude every potentially relevant alteration.
From variant to clinical question
The presence of EGFR, ALK, BRAF, ERBB2 (HER2), KRAS, or another alteration must be interpreted in its disease-specific context. A biomarker can be actionable in one tumor type, investigational in another, or unrelated to a proposed therapy.
Reading reports critically
Review considerations include variant nomenclature, allele fraction, potential germline implications when relevant, tumor purity, assay coverage, analytical limitations, and whether a reported alteration has sufficiently supported clinical significance.
How MPO supports review
MPO synthesizes provided genomic and pathology documentation into a research-grounded summary of molecular findings, evidence quality, possible therapeutic questions, and areas requiring clarification by the treating team.
Beyond the genomic panel
Molecular results should be interpreted alongside histology, stage, prior treatment, comorbidities and the clinical question. Genomic profiling can support precision oncology but does not independently determine care.
Related resource: OncoAtlas cancer evidence maps. Published profile: OncoDaily feature.